This article is from the source 'guardian' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.

You can find the current article at its original source at https://www.theguardian.com/world/2020/oct/27/covid-vaccine-uk-oxford-university-astrazeneca-works-in-all-ages-trials-suggest

The article has changed 3 times. There is an RSS feed of changes available.

Version 0 Version 1
Oxford Covid vaccine works in all ages, trials suggest Oxford Covid vaccine works in all ages, trials suggest
(about 4 hours later)
Vaccine being trialled by Oxford University and AstraZeneca offers hope for all age groupsVaccine being trialled by Oxford University and AstraZeneca offers hope for all age groups
One of the world’s leading Covid-19 experimental vaccines produces an immune response in both older and young adults, raising hopes of a path out of the gloom and economic destruction wrought by the novel coronavirus. One of the world’s leading Covid-19 experimental vaccines produces an immune response in older adults as well as the young, its developers say, raising hopes of protection for those most vulnerable to the coronavirus that has caused social and economic chaos around the world.
The vaccine, developed by the University of Oxford, also triggers lower adverse responses among elderly people, said the British drug maker AstraZeneca, which is helping to manufacture the vaccine, on Monday. Neither Oxford University nor its commercial partner AstraZeneca would release the data from the early trials showing the positive effects, which are being submitted to a peer-reviewed journal. But AstraZeneca confirmed the basic findings about the vaccine it calls AZD1222, which were shared at a closed academic meeting.
A vaccine that works is seen as a game-changer in the battle against coronavirus, which has killed more than 1.15 million people, shuttered swathes of the global economy and turned normal life upside down for billions of people. The phase 2 trials have shown that people over the age of 56 – and some over 70 – produced the same sort of antibody response as younger volunteers. Whether older people would be protected has always been a key question for the vaccines being developed. The body’s natural immune system and therefore its ability to fight any virus weakens with age, which is why the Covid death rate rises in older people.
“It is encouraging to see immunogenicity responses were similar between older and younger adults and that reactogenicity was lower in older adults, where the Covid-19 disease severity is higher,” an AstraZeneca spokesman said. The data also show that fewer side-effects – referred to by the scientists as “reactogenicity” – were reported in the older volunteers, which is encouraging, although it could mean that fewer of them reported issues such as a sore arm.
“The results further build the body of evidence for the safety and immunogenicity of AZD1222,” the spokesman said, referring to the technical name of the vaccine. “It is encouraging to see immunogenicity responses were similar between older and younger adults and that reactogenicity was lower in older adults, where the Covid-19 disease severity is higher. The results further build the body of evidence for the safety and immunogenicity of AZD1222,” said an AstraZeneca spokesman.
AstraZeneca did not provide detail of the data behind the statement or say when it would publish eagerly awaited late-stage phase 3 trial data, which would show whether the vaccine works well enough in large-scale trials for it to be approved. A vaccine that works is seen as a game-changer in the battle against coronavirus, which has killed more than 1.15 million people, shuttered swathes of the global economy and turned normal life upside down for billions of people. However, few think the first vaccines will be fully protective. They may instead reduce the severity of illness, so that people avoid hospital and deaths are reduced. They may also not last, so that boosters will be needed.
AstraZeneca said it hoped the vaccine may be ready for limited use within the coming months. “We anticipate efficacy read-outs from phase 2/3 trials between now and the end of the year, and if approved within countries, doses of the potential vaccine could be available for use before the end of the year,” said the spokesperson.
However, most experts outside the company, and the UK health secretary, Matt Hancock, expect it not to be available until 2021. Asked if some people could receive a vaccine this year, Hancock told the BBC: “I don’t rule that out but that is not my central expectation.”
Hancock said a vaccine was not yet ready but he was preparing logistics for a possible rollout, mostly in the first half of 2021. AstraZeneca has committed to mass manufacturing and has a capacity of 3bn doses – which equates to enough for 1.5 billion people globally getting the two-dose vaccine. It has also signed deals with manufacturers in other countries, such as India.
The final trials (phase 3), looking to see a significant difference in the numbers of deaths between those vaccinated and those who are not, are taking place in six countries. Trials in the US, which were paused after a volunteer in the UK became ill, have resumed. The other countries participating are South Africa, Brazil, Japan and India.
The vaccine is expected to be one of the first from big pharma to secure regulatory approval, along with one from Pfizer and BioNTech.The vaccine is expected to be one of the first from big pharma to secure regulatory approval, along with one from Pfizer and BioNTech.
The news that older people get an immune response from the vaccine is positive because the immune system weakens with age and older people are those most at risk of dying from the virus.
If it works, a vaccine would allow the world to return to some measure of normality after the pandemic.
The British health secretary, Matt Hancock, said a vaccine was not yet ready but he was preparing logistics for a possible rollout, mostly in the first half of 2021.
Asked if some people could receive a vaccine this year, he told the BBC: “I don’t rule that out but that is not my central expectation.”
Work began on the Oxford vaccine in January. Called AZD1222 or ChAdOx1 nCoV-19, the viral-vector vaccine is made from a weakened version of a common cold virus that causes infections in chimpanzees.Work began on the Oxford vaccine in January. Called AZD1222 or ChAdOx1 nCoV-19, the viral-vector vaccine is made from a weakened version of a common cold virus that causes infections in chimpanzees.
Immunogenicity blood tests carried out on a subset of older participants echo data released in July that showed the vaccine generated “robust immune responses” in a group of healthy adults aged between 18 and 55, the Financial Times reported earlier. Stephen Evans, professor of pharmacoepidemiology at the London School of Hygiene & Tropical Medicine, cautioned that no conclusions about the efficacy of the vaccine should be drawn until the data had been published.
“We need to see the data before concluding that the responses were ‘similar’,” said Stephen Evans, a professor of pharmacoepidemiology at the London School of Hygiene & Tropical Medicine. “In order to comment properly on this we need to see the data,” he said. “It is encouraging that the investigators suggest that the immune responses measured in the blood seem to show efficacy both above, as well as below, age 70. The later phase trials are needed to see if the immune responses translate into clinical efficacy in preventing infection. These will involve much larger numbers and it is wise to not be too optimistic until those trials have completed.”
He said that reactogenecity – the common side-effects of vaccines such as soreness and redness of the arm – was “often, but not always” associated with a vaccine’s immunogenicity. Raised antibody levels in the blood indicated but did not guarantee protection from the virus multiplying in the body, he said.
“Studies carried out in the first stage of development of a vaccine will result in choosing a dose that does not cause too much reactogenicity,” he said.
AstraZeneca has signed several supply and manufacturing deals with companies and governments around the world as it gets closer to reporting early results of the late-stage clinical trial.
It resumed the US trial of the experimental vaccine after approval by US regulators, the company said on Friday.
Staff at a London hospital trust have been told to be ready to receive the first batches of the Oxford-AstraZeneca vaccine, the Sun reported on Monday.